Eli Lilly and Company（LLY）— 圖表、結構與Closelook解讀

關於Eli Lilly and Company

Eli Lilly and Company（LLY）於美國交易所交易，產業分類為Healthcare。該股為HALO Growth 100的成分股。

Closelook公司評分綜合為66/100（動能70、品質92、估值37），基於7個模組 — 完整的三層拆解、圖表結構與歷史類比案例將於上方即時載入。

財報紀錄

在涵蓋的10次財報中，EPS優於預期9次、營收優於預期8次；財報後三日的反應為上漲4次 · 持平3次 · 下跌3次（截至2026-08-03的卡片）。 The calmest record in the series — and that is the finding. While the AI names swing ±15 to ±30 on their prints, Eli Lilly's entire ten-print distribution fits inside ±7.4%: nine EPS beats, a 4-3-3 reaction count, nothing violent in either direction. This is what a mega-cap looks like when the market believes the demand story and only argues about pace — the GLP-1 franchise as the anti-AI trade, repricing in single digits while the technology complex reprices in tens. It prints Wednesday morning at 1,125 — 9.9% off its high, above its 200-day — the same morning as Novo Nordisk: a head-to-head print in the one duopoly the tape trusts more than compute.

Eli Lilly and Company完整財報紀錄卡 →

closelook.net是一份投資研究日記 — 市場結構、指數成分與評分皆為我們自己的解讀，不構成投資建議。 相關頁面： LLY的即時新聞動態 · 指數比較 · 產業離散度 · 掃描器.